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ORIGINAL ARTICLE
Transient leukemia (TL) in neonates, also referred
to as transient myeloproliferative disorder or tran-
sient abnormal myelopoiesis, is characterized by
an excessive accumulation of leukemic blasts and
other hematologic abnormalities. It occurs com-
monly in neonates with Down syndrome1 or in
phenotypically normal neonates with chromo-
some 21 mosaicism,2,3 although it has also been
reported in neonates with a normal karyotype.4,5
There is a high incidence in TL of spontaneous
disappearance of blasts within the first few
months of life. However, in the first month of
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Background/Purpose: In a previous study, we demonstrated that in vitro cell growth stimulated by human
placental conditioned medium distinguished between transient leukemia (TL) and congenital acute myeloid
leukemia (AML) in neonates. We then sought to determine whether the application can be expanded if 
in vitro cell growths are stimulated by recombinant human cytokines including granulocyte-macrophage
colony-stimulating factor (rhGM-CSF), interleukin-3 (rhIL-3), stem cell factor (rhSCF) and thrombopoietin
(rhTPO).
Methods: Eight neonates with features indistinguishable from AML were studied. Seven patients had Down
syndrome and the eighth a normal phenotype. Bone marrow or peripheral blood mononuclear cells (MNC)
were cultured in the presence of rhGM-CSF+ rhIL-3+ rhSCF or of rhTPO alone. After incubation, granulocyte-
macrophage colony-forming units (CFU-GM)-derived colonies and clusters were scored on an inverted
microscope. Colony-forming units-megakaryocyte (CFU-MK)-derived colonies were counted with an in situ
CD61 immunostained dish. Liquid suspension cultures of MNC were stimulated by rhGM-CSF and/or rhTPO.
Results: CFU-GM-derived colonies and clusters from bone marrow and peripheral blood MNC revealed
normal patterns in seven patients. RhTPO-stimulated megakaryocyte colony formation was normal in one
patient. Cytospin smears of liquid suspension cultures all showed good myeloid or megakaryocytic matura-
tion consistent with TL rather than AML. One neonate died on the 2nd day of life, but in the seven remaining
patients, blasts disappeared from the peripheral blood within 10 months. Among four patients followed long-
term, one developed myelodysplastic syndrome at 21 months. This child was given tailored chemotherapy and
had a disease-free survival > 20 months.
Conclusion: In vitro cell growth stimulated by recombinant human cytokines can help to diagnose TL in
neonates. [J Formos Med Assoc 2007;106(5):365–371]
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life, it is generally difficult to differentiate TL
from congenital acute myeloid leukemia (AML).
Previously, we demonstrated that in vitro cell
growth stimulated by human placental condi-
tioned medium (HPCM) can distinguish between
these two disorders.6
Granulocyte-macrophage colony-stimulating
factor (GM-CSF) is a cytokine that promotes 
the proliferation and maturation of neutrophilic
precursors. The function of mature neutrophils
as well as the number and function of monocyte-
macrophage cells are also enhanced by GM-CSF.
The molecular sequence of endogenous human
GM-CSF was first identified in 1985. Since then,
trials of recombinant human GM-CSF (rhGM-CSF)
have demonstrated its diverse biologic effects as
playing a vital role in various hematopoietic as well
as immune functions.7,8
Interleukin-3 (IL-3) is known to be involved
in the growth and the differentiation of CD34+
progenitor cells into basophils, mast cells, den-
dritic cells (myeloid- or nonmyeloid-derived), and,
to a lesser extent, eosinophils and monocyte-
macrophages.8 In vitro studies have shown that
stem cell factor (SCF; also known as kit ligand,
mast cell growth factor, or steel factor) acts on
hematopoietic stem cells and progenitor cells.
Recombinant human SCF (rhSCF), in concert with
rhIL-3 or rhGM-CSF has been demonstrated to
encourage growth of granulocyte-macrophage
colony-forming units (CFU-GM) in both semi-
solid and liquid culture media.9
Thrombopoietin (TPO), the ligand for the 
c-mpl receptor (Mpl ligand, ML), is a major regu-
lator of platelet production in vivo. Recombinant
human TPO (rhTPO) alone can stimulate pro-
liferation and maturation of megakaryocytes in 
liquid suspension and in colony-forming units-
megakaryocyte (CFU-MK) progenitor assays.10 We
have studied the effects of rhTPO on megakaryo-
cyte colony formation from control human bone
marrow cells and human leukemia cells at diag-
nosis. Our previous work showed that rhTPO
alone effectively stimulates megakaryocyte colony
formation in histologically normal-looking bone
marrow. In contrast, rhTPO stimulates leukemic
colony formation only in patients with acute
megakaryocytic leukemia (AMKL).11
In this study, our goal was to demonstrate
whether in vitro cell growth stimulated by recom-
binant human cytokines can differentiate TL
from AML in the neonatal period.
Materials and Methods
Between March 1995 and July 2003, eight consec-
utive neonates with hematologic and clinical find-
ings suggestive of AML were studied. Seven patients
had Down syndrome and the eighth had a normal
phenotype. Congenital infection and hemolytic
anemia were carefully excluded in all eight.
Bone marrow and peripheral blood smears
were stained with a modified version of the 
Romanowsky method.12 Immunophenotyping was
performed by flow cytometry using monoclonal
antibodies against human leukocyte antigen
(HLA)-DR, CD34, CD19, CD10, sIg (κ and λ),
CD2, CD3, CD4, CD8, CD13, CD14, CD33 and
CD61 as previously described.13 For the assess-
ment of a megakaryocytic proliferative disorder,
at least 15% of the blast cells need to be positive
for the platelet-specific monoclonal antibody,
CD61. Samples were defined as positive for any
of the other cell markers if > 30% of the cells
were fluorescence-reactive. Leukemic cells were
cytogenetically analyzed using banded chromo-
somes from unstimulated peripheral blood or
direct and 24-hour-cultured preparations of fresh
bone marrow, as described previously.14 Chromo-
some abnormalities were designated by using
the 1995 International System for Human Cyto-
genetics Nomenclature.15
Cells
Bone marrow samples were centrifuged over Ficoll-
Paque (Pharmacia Biotech, Uppsala, Sweden) at
2600 rpm for 20 minutes at room temperature.
The mononuclear cells (MNC) recovered from the
interface were washed three times by centrifuga-
tion at 2000 rpm for 10 minutes and then resus-
pended in Iscove’s modified Dulbecco’s medium
TL in neonates
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(IMDM, Gibco, Grand Island, NY, USA). Adherent
cells were then removed according to previously
described methods.11
Recombinant human cytokines
The recombinant human cytokines used included
rhGM-CGF, rhIL-3, rhSCF and rhTPO (provided
by Kirin Brewery, Tokyo, Japan).
Cell culture
Bone marrow MNC were cultured at a concentra-
tion of 2 × 105 cells and peripheral blood MNC 
at 1 × 106 cells in a single layer system with 1 mL
α-medium containing 0.3% agar, 20% fetal calf
serum (FCS), rhGM-CSF 12.5 ng, rhIL-3 50 ng, and
rhSCF 100ng. After 7 days of incubation in 5% CO2
and fully humidified air at 37°C, GM-CFU-derived
colonies and clusters on agar plates were scored
on an inverted microscope. Aggregates of 8–40 cells
were counted as clusters and > 40 cells as colonies.
CFU-MK culture was performed using an
agarose-serum free system,16 1 mL containing
rhTPO 100 ng. After incubation for 14 days, the
whole dish was fixed and refrigerated until im-
munocytochemical staining with CD61 in situ. 
A cluster of three or more CD61(+) cells seen
under light microscope was counted as a CFU-MK-
derived colony.11
The bone marrow or peripheral blood MNC
were also suspended in 1 mL α-medium contain-
ing 15% FCS and rhGM-CSF 12.5ng and/or rhTPO
100 ng. Cells were harvested 7 days later and 
cytospin preparations were made and stained with
the modified Romanowsky system (rhGM-CSF)
or immunostain by CD61 (rhTPO).
Since it is often difficult to obtain enough
cells from bone marrow aspiration in neonates,
peripheral blood cells, which comprised 16–80%
of blasts, were also used. CFU-GM and CFU-MK
assays, and liquid suspension cultures of bone
marrow or peripheral blood were performed to
explore the characteristics of hematopoiesis in our
patients.
Control
The bone marrow samples from 14 non-Down
syndrome children with AML were collected 
as positive controls of CFU-GM assay stimu-
lated by rhGM-CSF + rhIL-3 + rhSCF. According
to the FAB (French-American-British) classification
of AML,17–19 there were one M0, two M1, three
M2, two M3, one M4, three M5 and two M7
(AMKL). The genetic abnormalities included two
t(8;21), two t(15;17), one t(1;22) and one tri-
somy 8 and eight normal karyotype. Two AMKL
patients were also used in the study of CFU-MK
assay stimulated by rhTPO.
Results
The characteristics of all eight neonates at diag-
nosis are summarized in Table 1. The hematologic
values varied substantially, with white blood cell
counts ranging from 11.5 to 180 × 109/L and
blasts from 16% to 89%. Patients 4, 6, and 7 had
Table 1. Characteristics of patients at presentation
Patient
Age
Sex
WBC PB blasts Hb Platelets Palpable liver Palpable spleen
(d) (× 109/L) (%) (g/dL) (× 109/L) (cm) (cm)
1 2 M 104.9 32 19.3 228 2 0
2 5 M 59.5 62 13.3 126 0 0
3* 5 M 11.5 16 13.0 28 3 0
4 1 M 180.0 78 15.3 500 10 1.5
5 11 F 132.6 89 12.6 20 4 6
6 2 M 32.7 35 10.8 146 4 0
7 1 F 20.9 35 12.9 634 12 6
8 5 M 93.2 80 15.8 104 2.5 1
*Patient with normal phenotype. WBC = white blood cell; PB = peripheral blood; Hb = hemoglobin.
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myelofibrosis, with little yield on bone marrow
aspiration. Immunophenotyping was performed
for six patients, including three in whom it was
done using peripheral blood. The immunopheno-
typic data varied, with CD61 positivity (> 15%)
in four of the six patients. The positive results
were 40% in Patient 4, 28% in Patient 6, 25% in
Patient 7 and 16% in Patient 8. The remaining
Patients 2 and 5 expressed positivity (> 30%) of
CD34, HLA-DR and CD33. They showed 5% and
6% CD61 stained cells, respectively.
The results of CFU-GM and CFU-MK assays
are shown in Table 2. CFU-GM assays of five bone
marrow samples (Patients 1, 4, 5, 6 and 8) dis-
closed normal ratios of clusters to colonies as com-
pared with normal historical controls.6 In contrast,
lack of colony formation (median 0, range 0–6.5)
with poor (down to 0) or extensive cluster forma-
tion (up to 1315), with a median of 8.5, were ob-
served in 14 positive controls of AML bone marrow
samples. These results generated the ratios of clus-
ters to colonies to an abnormally wide range of
4.25 to infinity. The number of CFU-MK-derived
colonies from Patient 2 was similar to those 
of normal historical controls,11 rather than the
extensive megakaryoblast proliferation seen in
two positive controls with AMKL. The results of
cytospin smears of liquid suspension cultures are
summarized in Table 3. After stimulation by rhGM-
CSF alone, cytospin smears of liquid suspension 
cultures from five bone marrow and four periph-
eral blood samples showed good myeloid and
macrophage maturation without an increase of
myeloblasts. Liquid suspension cultures of bone
marrow and peripheral blood cell from Patient 8
were also stimulated by rhTPO and the cytospin
smears from both samples showed an increase in
mature megakaryocytes. Bone marrow cells from
Patients 4 and 6 were co-stimulated with rhGM-
CSF and rhTPO, with the resulting cytospin smears
demonstrating good myeloid, macrophage and
megakaryocytic maturation without an increase
of myeloblasts or megakaryoblasts. In patients
with an increased number of CFU-GM-derived
colonies or clusters, liquid suspension culture 
results were all normal.
Since none of the eight neonates had in vitro
cell growth patterns suggestive of AML, TL was di-
agnosed in all eight. Accordingly, no chemotherapy
was given. Patient 7, who had respiratory failure,
Table 2. CFU-GM or CFU-MK assays stimulated by recombinant human cytokines 
Patient
Bone marrow Peripheral blood
Cluster Colony Cluster/colony ratio (0.5–5.1)6 Cluster Colony
CFU-GM assay stimulated by rhGM-CSF + rhIL-3 + rhSCF
1 82 19.5 4.2 808 327.5
3 ND ND ND 0.5 0
4 1224 1868 0.7 ND ND
5 282.5 193 1.5 ND ND
6 437 422 1.0 ND ND
7 ND ND ND 1127 420
8 440 144 3.1 368 928
Positive controls (14 AML)* 0–1315 (8.5) 0–6.5 (0) 4.25 to infinity – –
CFU-MK derived colonies stimulated by rhTPO
2 – 0.5 –
Positive controls (2 AMKL) – Numerous –
*Data for positive controls are presented as range (median). The number of colonies and clusters for bone marrow cells is given per
2 × 105 mononuclear cells and for peripheral blood cells per 1 × 106 mononuclear cells. CFU-GM = colony-forming units-granulocyte-
macrophage; CFU-MK = colony-forming units-megakaryocyte; rh = recombinant human; GM-CSF = granulocyte-macrophage colony-
stimulating factor; IL-3 = interleukin-3; SCF = stem cell factor; ND = not done; TPO = thrombopoietin.
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acute renal failure, and liver dysfunction, died
after withdrawal of life support on the 2nd day 
of life. In the other seven patients, the blasts 
disappeared from the peripheral blood within 
10 months. Three patients subsequently died be-
cause of other conditions (tetralogy of Fallot at
surgery, annular pancreas after surgery, and acute
renal failure). Among the four patients (three
with Down syndrome and one with a normal
phenotype) followed long-term, Patient 6 devel-
oped myelodysplastic syndrome at the age of 21
months. He was given chemotherapy with lower
doses tailored for Down syndrome, consisting of
cytarabine and idarubicin (7 + 3) as induction
therapy and three courses of cytarabine sequen-
tially combined with VP-16, L-asparaginase and
VP-16 as post-remission therapy. As of June 30,
2005, disease-free survival was longer than 20
months. The other three patients aged 24, 56,
and 66 months were alive without leukemia.
Discussion
Children with Down syndrome have a 10- to 20-
fold increased risk of developing leukemia.20 Based
on the screening of peripheral blood smears in a
small cohort of newborns with Down syndrome,
Doyle and Zipurksy estimated that approximately
10% of such infants have TL.21 When fetal cases are
taken into consideration, the incidence could be
as high as 20%.22 Spontaneous disappearance of
blasts from TL is observed in the majority of cases
within the first few months of life. However, of
those who enter spontaneous remission, 13–33%
subsequently develop a hematologic disorder, most
frequently AMKL, usually diagnosed at less than
3 years of age (mean age, 16 months).23 TL may
also develop in neonates with mosaic trisomy 
21 karyotypes and infrequently in those without
a known chromosomal abnormality.2–5,23
Though our sample size was limited, the clini-
cal features at diagnosis, the diverse results of sur-
face antigen expression, and the relapse rate before
3 years of age were quite similar to the characteris-
tics of patients in published large-scale reviews.23,24
Based on the results of in vitro cell growth patterns,
all the eight patients were diagnosed with TL. In
the seven patients who survived the first week of
life, blasts disappeared from the peripheral blood
within months. Only one patient who subse-
quently relapsed with myelodysplastic syndrome
responded well to chemotherapy.
There is no single conventional test which
can differentiate congenital AML from TL in all
cases. Although most patients with TL have a sig-
nificant megakaryocytic component, the major-
ity of blasts lack definitive identifiable features.
Table 3. Liquid suspension cultures stimulated by recombinant human cytokines
Patient
rhGM-CSF rhGM-CSF + rhTPO rhTPO
Bone marrow Peripheral blood Bone marrow Bone marrow Peripheral blood
1 Good myeloid maturation Good myeloid maturation ND ND ND
3 ND Good myeloid maturation ND ND ND
4 Good myeloid and ND Good myeloid and ND ND
macrophage maturation, macrophage maturation,
blasts < 5% blasts < 5%; mature
megakaryocytes
5 Good myeloid maturation ND ND ND ND
6 Good myeloid maturation ND Megakaryoblast < 10% ND ND
7 ND Good myeloid and ND ND ND
macrophage maturation
8 Good myeloid and Good myeloid and ND Increase in mature Increase in mature
macrophage maturation macrophage maturation megakaryocytes megakaryocytes
rh = recombinant human; GM-CSF = granulocyte-macrophage colony-stimulating factor; TPO = thrombopoietin; ND = not done.
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Platelet-associated antigens, such as CD41 and
CD61, are commonly expressed in TL. Morpho-
logic, immunologic, and cytogenetic data suggest
that TL may involve the proliferation of bone mar-
row cells that are a common progenitor for the ery-
throid and megakaryocytic lines.25–27 Regardless,
these features are still not specific enough to dis-
tinguish between TL and congenital AML.
Using agar cultures of bone marrow and periph-
eral blood, Moore et al showed that none of 108
untreated AML cases had both colony and cluster
growth patterns within the normal range.28 Shih
and Chang demonstrated that cultures from bone
marrow cells of 62 untreated AML were charac-
terized by lack of normal colony formation with
growth of varying numbers of clusters, ranging
from no growth at all or excessive microcluster
formation.29 In contrast, in reports of three
neonates with Down syndrome and TL, normal
colony formation was found in methylcellulose
semisolid culture.30 A normal ratio of clusters to
colonies was shown in two newborn babies with
Down syndrome and TL.31 By extending the ap-
plicability of the semisolid agar system to liquid
suspension cultures, our previous study demon-
strated that in vitro cell growth was helpful in dif-
ferentiating TL from AML.6
Before the emergence of recombinant human
cytokines, HPCM was widely used as a source of
colony-stimulating activity. We chose recombinant
human cytokines instead because they are stan-
dardized preparations which can easily be titrated
so that use in different laboratories can provide
replicable results. With stimulation by rhGM-CSF+
rhIL-3 + rhSCF, the CFU-GM assays from 14 posi-
tive AML controls consistently showed very abnor-
mal in vitro cell growth patterns which contrasted
to the neonatal TL which invariably revealed a nor-
mal in vitro cell growth pattern. The results in the
one patient with a CFU-MK assay of bone marrow
cells after stimulation by rhTPO were similar to
those of normal historical controls. In contrast, both
positive AMKL controls disclosed extensive CFU-
MK derived colonies. Cytospin smears of liquid sus-
pension cultures afford direct observation of the
differentiation and maturation of hematopoietic
cells. Our smears, either from bone marrow and
peripheral blood, both showed good myeloid and
megakaryocytic maturation without an increase
in myeloblasts or megakaryoblasts.
For such neonates who had higher percent-
ages of blasts in peripheral blood than those in the
bone marrow, their bone marrow was hard to 
aspirate due to their smaller body size; but we
successfully further expanded the capacity to dif-
ferentiate TL from congenital AML previously by
using HPCM stimulation6 to using recombinant
human cytokine stimulation in this study. The
methods reported here using peripheral blood 
as a substitute of bone marrow may provide an
alternative diagnostic tool.
Recent studies discovered that acquired muta-
tions of GATA1 are the most specific genetic markers
linked to Down syndrome AMKL. Mutations in
GATA1 are also shown in TL blasts.32,33 To date, the
mutations have never been detected in samples
from Down syndrome patients with other leuke-
mias, including those with ALL or non-AMKL
AML.34 Our method may provide a useful diagnos-
tic adjunct especially for the neonatal TL cases
whose status of GATA1 mutation is uncertain or
unavailable.
In conclusion, our study demonstrates in vitro
cell growths stimulated by recombinant human
cytokines, including rhGM-CSF, rhIL-3, rhSCF and
rhTPO can help to diagnose TL in neonates.
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